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Abstract 
Background: Breast cancer is the most frequent malignancy in women and drug resistance is the major obstacle 
for its successful chemotherapy. In the present study, we analyzed the involvement of an oncofetal gene, sal‑like 4 
(SALL4), in the tumor proliferation and drug resistance of human breast cancer.
Results: Our study showed that SALL4 was up‑regulated in the drug resistant breast cancer cell line, MCF‑7/ADR, 
compared to the other five cell lines. We established the lentiviral system expressing short hairpin RNA to knockdown 
SALL4 in MCF‑7/ADR cells. Down‑regulation of SALL4 inhibited the proliferation of MCF‑7/ADR cells and induced the 
G1 phase arrest in cell cycle, accompanied by an obvious reduction of the expression of cyclinD1 and CDK4. Besides, 
down‑regulating SALL4 can re‑sensitize MCF‑7/ADR to doxorubicin hydrochloride (ADMh) and had potent synergy 
with ADMh in MCF‑7/ADR cells. Depletion of SALL4 led to a decrease in IC50 for ADMh and an inhibitory effect on 
the ability to form colonies in MCF‑7/ADR cells. With SALL4 knockdown, ADMh accumulation rate of MCF‑7/ADR cells 
was increased, while the expression of BCRP and c‑myc was significantly decreased. Furthermore, silencing SALL4 also 
suppressed the growth of the xenograft tumors and reversed their resistance to ADMh in vivo.
Conclusion: SALL4 knockdown inhibits the growth of the drug resistant breast cancer due to cell cycle arrest and 
reverses tumor chemo‑resistance through down‑regulating the membrane transporter, BCPR. Thus, SALL4 has poten‑
tial as a novel target for the treatment of breast cancer.
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Background
Breast cancer, the most common neoplasm, is the lead-
ing cause of cancer-induced death in women worldwide 
[1, 2]. Surgery combined with adjuvant therapy, such as 
chemotherapy and radiotherapy, may have increased 
the patient survival rate in some way. Unfortunately, 
advanced and recurrent breast cancer still has very poor 
prognosis due to the primary or secondary resistance 
to chemotherapy drugs. Chemo-resistance that limits 
the therapeutic potential of anticancer drugs, result-
ing in failure of cancer treatment, still remains the main 
obstacle in terms of successful treatment of breast can-
cer [3, 4]. Therefore, novel effective attempts to over-
come chemo-resistance are urgently needed in order 
to improve the outcome of patients with advanced and 
recurrent breast cancer.
The mechanism of chemo-resistance is very complex, 
but the overexpression of some ATP-binding cassette 
(ABC) transporters and cancer stem cells, are two main 
Open Access
BMC Molecular Biology
*Correspondence:  phdhanbaosan@126.com 
†Yuan‑Yuan Chen, Zhi‑Zhen Li and Yuan‑Yuan Ye contributed equally to 
this work
1 Department of General Surgery and Laboratory of General Surgery, 
Xinhua Hospital, Affiliated with Shanghai Jiao Tong University, School 
of Medicine, No. 1665 Kong Jiang Road, 200092 Shanghai, China
Full list of author information is available at the end of the article
Page 2 of 11Chen et al. BMC Molecular Biol  (2016) 17:6 
causes of chemo-resistance [5–8].Interestingly, recent 
studies have shown that sal-like 4 (SALL4) gene, a mem-
ber of the mammal homologs of Drosophila homeotic 
gene spalt, is shared by stem cells with tumor cells pro-
moting their proliferation and conferring drug resist-
ance on them. SALL4 gene maps to chromosome 20q13 
in human and encodes zinc-finger transcription factor 
maintaining self-renewal and pluripotency of embry-
onic stem cells through a variety of signaling pathways, 
transcription factors, and epigenetic modulators [9–16]. 
And SALL4 gene mutations are known to cause Oki-
hiro syndrome, an autosomal dominant disease involv-
ing dysplasia of multiple organs [17]. In mice, SALL4 
homozygous knockout is embryonic lethal, and Ma et al. 
[18] reported that SALL4 can function as an oncogene 
in leukemogenesis by using a transgenic mouse model 
with SALL4 overexpression in most organs. Thereafter, 
SALLL4 aberrant expression in hematopoietic stem cells, 
in the leukemic cells of AML patients, and in some solid 
tumors has been reported by various groups [19–22]. 
Up-regulating SALL4 in cancer cells can promote their 
proliferative and invasive abilities. The overexpression of 
SALL4 in tumor patients often correlates with adverse 
progression and poor prognosis. Besides, the expression 
of SALL4 is higher in drug resistant primary acute mye-
loid leukemic patients than those from drug-responsive 
cases. SALL4 characterizes a feature of drug resistance 
through the maintenance of side population cancer stem 
cells and affects the side population cells by regulation of 
ABC drug transport genes ABCG2 and ABCA3 in leu-
kemic cells [23]. In liver cancer, SALL4 also enhances 
chemo-resistance by up-regulating ABCG2 [24]. In endo-
metrial cancer, however, SALL4 promotes tumor chemo-
resistance by activating c-myc to regulate MDR1/P-gp 
[25]. Furthermore, silencing SALL4 can enhance the 
chemo-sensitivity of tumor cells to anticancer drugs in 
liver cancer, endometrial cancer and lung cancer [26, 
27]. Nevertheless, studies on the relation between SALL4 
and drug resistance and chemotherapeutic sensitivity in 
breast cancer are still lacking.
The human breast cancer resistance protein (BCRP) is 
encoded by ABCG2 gene and it is a member of the G sub-
family of the large ABC transporter superfamily [28, 29]. 
MDR1, also named ABCB1, encodes P-glycoprotein(P-
gp) and it is one of the earliest ABC transporters to be 
identified. The high expression of MDR1 was found in 
the majority of breast cancer tissues and human breast 
cancer drug-resistant cells [30]. P-gp and BCRP were 
considered to be responsible for the majority of drug 
efflux in human cancer. A rise in their expression had 
something to do with a poor prognosis in many types of 
cancer. C-Myc gene encodes an evolutionarily conserved 
basic transcription factor and its overexpression is closely 
linked to chemotherapy resistance. In addition, overex-
pression c-myc can up-regulate the expression of BCRP 
in human mammary epithelial cells [31]. Therefore, we 
are interested in determining whether P-gp, BCRP and 
c-Myc are related with SALL4 involved in chemotherapy 
resistance in breast cancer.
In this study, we confirmed that SALL4 was overex-
pressed in the drug resistant cell line, MCF-7/ADR, and 
we down-regulated SALL4 gene in MCF-7/ADR through 
the lentiviral-mediated short hairpin RNA (shRNA) 
interference system. Then we examined the effects of 
SALL4 in MCF-7/ADR cells on proliferation and sensi-
tivity to doxorubicin hydrochloride (ADMh) in vitro and 
in vivo, and explored the possible molecular mechanisms 
underlying these effects, to provide experimental evi-
dence for the potential application of SALL4 gene as a 
therapeutic target in breast cancer.
Methods
Cell lines and culture
The human breast cancer cell lines, MCF-7, MDA-
MB-231, SK-BR-3, ZR-75-1 and the human mammary 
epithelial cell line, HBL-100, were purchased from Cell 
Bank of the Chinese Academy of Science (Shanghai, 
China). Human multidrug resistant breast cancer cell line, 
MCF-7/ADR, was obtained from the Cancer Institute of 
Zhejiang University. HBL-100 was cultured in RPMI-1640 
medium (Gibco-Life Technologies, Grand Island, NY, 
USA) supplemented with 10  % fetal bovine serum (FBS, 
Gibco) as well as 1  % penicillin–streptomycin (Gibco). 
The other cells were all cultured in Dulbecco modified 
Eagle medium (DMEM, Gibco), supplemented with 10 % 
FBS and 1 % penicillin–streptomycin. Cells were all pas-
saged by trypsinization every 2–3 days and maintained at 
37 °C in 5 % CO2. And all cells were cultured following the 
guidelines of Laboratory of Xinhua Hospital, affiliated to 
Shanghai JiaoTong University, School of Medicine, China.
Drugs and antibodies
Doxorubicin hydrochloride (ADMh) and Verapamil were 
purchased from Sigma Chemical Co. (St. Louis, MO, 
USA). For in vitro studies, they were dissolved in Stroke-
physiological saline solution (NS, NJCTT Pharmaceuti-
cal Co., Ltd, Nangjing, China) to create a stock solution 
(10  mmol/L), which was stored at −20  °C. To prepare 
working solutions, the stock solution was further diluted 
with culture media to yield the desired ADMh concentra-
tion. Primary antibodies against P-gp (goat-anti-rabbit) 
were purchased from Sigma Chemical Co. (St. Louis, 
MO, USA). Primary antibodies against c-myc, SALL4, 
BCRP, GAPDH and secondary antibodies (goat-anti-
rabbit) were purchased from Cell Signaling Technology 
(Danvers, MA, USA).
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Lentivirus‑mediated RNA interference and transfection
According to the gene data of SALL4 (NM-020436) in 
GenBank, the designed sequence of the short hairpin 
RNA (shRNA) used to target SALL4 was 5′-GCCT 
TGAAACAAGCCAAGCTA-3′. And the sequence of the 
negative control shRNA was 5′-TTCTCCGAACGTG 
TCACGT-3′.The shRNAs were synthesized and inserted 
into the pGMLV-SC5 lentivirus core vector containing 
a cytomegalovirus-driven enhanced green fluorescent 
protein (GFP) reporter gene. Recombinant lentiviruses 
expressing SALL4-shRNA (Lv-shSALL4) or negative con-
trol shRNA (Lv-shNC) were produced by Genomeditech 
Co.Ltd (Shanghai, China). The experiment of MCF-7/
ADR cells set up an experimental group (Lv-shSALL4), 
the negative control group (Lv-shNC) and blank control 
group (CON). MCF-7/ADR cells were infected with con-
centrated virus in serum-free medium. The supernatant 
was replaced with complete culture medium after 24  h. 
After being transfected for 96  h, mRNA and protein 
expression of SALL4 in the infected cells was validated by 
quantitative real-time PCR (qRT-PCR) analysis and west-
ern blot assays.
Quantitative real‑time PCR (qRT‑PCR)
Total RNA was extracted from the control and transfected 
cells using Trizol reagent (Takara, Shiga, Japan) and 
reverse transcribed into cDNA with the M-MLV Reverse 
Transcriptase (Invitrogen, Carlsbad, CA). RNA expres-
sion was measured by qRT-PCR using the SYBR-Green 
method (Takara) according to the manufacturer’s instruc-
tions. The relative expression level of the target gene 
was calculated by 2−ΔΔCT (ΔCT =  CTtarget −  CTGADPH, 
ΔΔCT  =  ΔCTtarget  −  ΔCTcon) and normalized to the 
relative expression detected in the corresponding 
control cells, which was defined as 1.0 [32]. GAPDH 
was used as the referral gene. And HBL-100 cells 
was used as the control cells in calculating the rela-
tive expression of SALL4 among the six breast cell 
lines. Primer sequences were as follows: GAPDH for-
ward, 5′-GAGAGACCCTCACTGCTG-3′; and reverse, 
5′-GACTGGTAGATGACAAGGTGC-3′; SALL4 for-
ward, 5′-CCAATAGTCAAGAAAGC-3′; and reverse, 
5′-ATCGCTCCGACCTTCCATC-3′; ABCG2 forward, 
5′-TTATCCGTGGTGTGTCTGGA-3′; and reverse, 
5′-GATGATTGTTCGTCCCTGCT-3′; c-myc forward, 
5′-GCTGCTTAGACGCTGGATTT-3′; and reverse, 
5′-CGAGGTCATAGTTCCTGTTGG-3′; MDR1 for-
ward, 5′-CCGCTGGTTTCCTTTAG-3′; and reverse, 
5′-CTTCTTTGCTCCTCCATTGC-3′.
Western blot analysis
Western blot analysis was carried out as described before 
[33]. Briefly, cellular proteins were extracted using lysis 
buffer (Beyotime, Shanghai, China) from the treated 
cells. Protein concentrations were quantified by the BCA 
protein assay reagent kit (Beyotime) according to the 
manufacturer’s instructions. Equal quantities of cellular 
proteins were resolved by SDS-PAGE and then electro-
phoretically transferred to nitrocellulose membranes 
(Millipore, Bedford, MA, USA). Each membrane was 
blocked with 5  % skim milk and immuneblotted with a 
primary antibody. After incubation with a secondary 
antibody, the bands were visualized by enhanced chemi-
luminescence (Millipore, Billerica, MA). GAPDH was 
used as the loading control.
Cell viability assay
The cells were inoculated into 96-well plates and treated 
according to the experimental grouping requirements. 
The 10 ul of CCK-8 (Dojindo, Kumamoto, Japan) was 
added to each well of the plate, and the plates were main-
tained at 37  °C and 5  % CO2 for 3  h, and the absorb-
ance at 450 nm (A450) was measured with a microplate 
reader (Bio-Tek, Winooski, VT, USA). The results 
were expressed as the average of three independent 
experiments. The absorbance values were used to draw 
growth curve and calculate the relative proliferation 
rate (RPR). The inhibition ratios (IR), resistance indi-
ces (RI) and the changes in IC50 values (the concentra-
tion of drug inhibiting 50 % of the cells) at 24 and 48 h 
were also calculated based on A450. RPR is the ratio 
of the A450 value of the tested day and that of the first 
day in a group cells. And RI is the ratio of IC50 values 
of resistant cells and that of parental cells. IR, PRP and 
RI were calculated according to the following formu-
las: PRP  =  A450 (the tested day)/A450 (the first day), 
IR  =  [1  −  (A450treatment  −  A450blank)/(A450con-
trol − A450blank)] × 100 %, and RI = IC50(MCF-7/ADR 
cells)/IC50(MCF-7 cells).
Cell cycle analysis
MCF-7/ADR cells infected by the recombinant lentivi-
ruses or not were inoculated into 6 well plates for 48 h. 
Then, cells were harvested by trypsinization, washed 
twice in cold PBS, and fixed in 70 % ethanol at 4 °C over-
night. Next, the cells were washed and resuspended in 
cold PBS and incubated in a solution of 10 mg/mL RNase 
and 1 mg/mL propidium iodide (Sigma-Aldrich) at 37 °C 
in the dark for 30 min. Finally, the samples were analyzed 
by flow cytometry (BD Biosciences). The percentage 
of cells in the G1, S, and G2/M phases was determined 
using Cell Quest acquisition software (BD Biosciences).
Colony formation assay
Cells in the logarithmic growth phase were aliquoted 
as single cell suspension and 400 cells were placed into 
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each well of 6-well plates (Corning, Corning, NY, USA). 
After adherence, cells were treated with ADMh (5 and 
10 umol/L) for 12 h. Then, all plates were incubated for 
14 days to allow colony formation. Next, cells were fixed 
with 4 % paraformaldehyde and stained with 0.1 % crys-
tal violet (Sigma-Aldrich) for 20 min. After washing, the 
plates were air-dried, and stained colonies were photo-
graphed with a microscope (Leica, Wetzlar, Germany). 
The total number of colonies (>50 cells/colony) was 
counted.
Analysis of intracellular accumulation of ADMh
The assay of intracellular accumulation of ADMh were 
conducted as previously described [34]. In short, the 
intracellular accumulation of ADMh in MCF-7/ADR 
cells and parental MCF-7 cells was measured by flow 
cytometry (BD Biosciences). The excitation and emis-
sion wavelengths of ADMh were 488 and 566 nm, respec-
tively. The cells were incubated with ADMh (5  umol/L) 
for 2  h under normal cell culture conditions. Next, the 
cells were removed from the culture dishes by trypsini-
zation and centrifuged and suspended in ice-cold PBS. 
Then, the samples were analyzed by flow cytometry (BD 
Biosciences). In another experiment, to show the effect 
of P-gp and BCRP inhibitor on the anthracycline drugs 
accumulation, cells were preincubated with Verapamil 
(5  umol/L) for 30  min and then incubated with ADMh 
(5 umol/L) for 2 h. Cellular drug fluorescence was meas-
ured using an argon laser at FL2 channel. For all samples 
20,000 cells were counted and the analysis was performed 
using flow cytometry.
Experimental animals
This study was approved by the ethics committee of Xin-
hua Hospital of Shanghai Jiaotong University,School of 
Medicine, China. Female BALB/c nude mice, 4–6 weeks 
old, were purchased from Shanghai SLAC Labora-
tory Animal Co., Ltd. (Shanghai, China). The mice were 
housed in groups of five in specific pathogen-free con-
ditions following the guidelines of Laboratory Animals 
and the Ethics Committee of Xinhua Hospital, affiliated 
to Shanghai JiaoTong University. To explore the effects 
of SALL4 on tumor growth and drug resistance in vivo, 
MCF-7/ADR cells (3 × 106) stably expressing Lv-shRNA 
suspended in 150  ul PBS were subcutaneously injected 
into the right axilla of the mice. On Day 7, these mice 
carrying xenograft tumor of MCF7/ADR cells infected 
with Lv-shSALL4 were randomly divided into two groups 
(5 mice/group). The first group received an intraperito-
neally (i.p.) injection of NS every 3  days and the other 
group were administered an i.p. injection of ADMh 
(3 mg/kg) every 3 days. Simultaneously, these mice car-
rying xenograft tumor of MCF7/ADR cells infected with 
Lv-shNC were also randomly divided into two groups (5 
mice/group) and subsequently treated as the Lv-shRNA 
group. On Day 20, all nude mice were anesthetized with 
CO2, and the tumor tissue was excised from mice and 
weighed.
Statistical analysis
Statistical analyses were carried out using GraphPad 
Prism 5.0 software (La Jolla, CA, USA). All assays were 
performed independently three times and data were 
expressed as the mean ± SD. The independent Student’s 
t test was used to compare the means of two groups. 
The analysis of variance (ANOVA) test was performed 
in 2  ×  2 factorial design to test a synergistic effect of 
shRNA-driven knockdown of SALL4 and drug treatment 
on tumor growth. The difference was considered statisti-
cally significant when P < 0.05.
Results and discussion
SALL4 is overexpressed in chemo‑resistant breast cancer 
cell line MCF‑7/ADR
To assess the role of SALL4 in the drug resistant breast 
cancer cells, we detected the endogenous expression 
of SALL4 in the normal mammary epithelial cell line 
HBL-100 and five breast cancer cell lines including 
MCF-7, MDA-MB-231, SK-BR-3, ZR-75-1 and MCF-7/
ADR by qRT-PCR and Western blot. MCF-7, MDA-
MB-231, SK-BR-3 and ZR-75-1 cell lines are sensitive 
to chemotherapy drugs such as anthracycline, taxane 
and so on. But MCF-7/ADR cells are resistant to many 
drugs, despite the diversity in their chemical structures 
and mechanisms of action. And it was established from 
MCF-7cell line by exposing to adriamycin with step-
wise increasing concentration [35]. The relative expres-
sion level of SALL4 was significantly higher in MCF-7/
ADR cells compared with that in the other five cell 
lines (P < 0.05, Fig. 1a). And the results of western blot 
of SALL4 were consistent with the results of mRNA 
(Fig.  1b). Previously, gain- and loss-of-function studies 
have revealed that overexpression of SALL4 was cor-
related with chemo-resistance in myeloid leukemia, 
endometrial cancer, lung cancer and liver cancer. Taken 
together, these results illustrate that SALL4 may also play 
an important role in regulating the resistance to chemo-
therapeutics in breast cancer.
Knockdown of SALL4 inhibits cell proliferation
To explore the effects of SALL4 on the chemo-resistant 
breast cancer, we established a lentiviral system express-
ing shRNA to transfect MCF-7/ADR cells. The trans-
fection efficiency was confirmed by qRT-PCR (Fig.  2a) 
and western blot (Fig.  2f ).SALL4 mRNA detection in 
the cells showed the shRNA sequence targeting SALL4 
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significantly inhibited SALL4 expression compared with 
the CON group (P < 0.001). On the contrary, the nega-
tive control sequence (Lv-shNC) did not show statisti-
cally effect on the target gene (P  >  0.05). The results of 
western blot of SALL4 also coincided exactly with the 
results of mRNA. These data suggest that we have suc-
cessfully down-regulated SALL4 in MCF-7/ADR cells by 
the approach lentivirus-mediated shRNA interference.
By comparing the growth curves of MCF-7/ADR cells 
with or without SALL4 knockdown, SALL4 knock-
down seemed to significantly inhibit the cell viability. 
The cell viability in SALL4 knockdown group was sig-
nificantly lower than that in the CON group at the third 
day (P  <  0.05), and the inhibitory effect on cell viabil-
ity became more obvious at the fourth and fifth day 
(P  <  0.001, Fig.  2b). The relative proliferation rate also 
indicated cell proliferation was markedly reduced in Lv-
shSALL4 group since the third day when compared to the 
CON group (P < 0.05, Fig. 2c).But there was no observ-
able difference between the CON group and the Lv-
shNC group (P > 0.05). According to those data, SALL4 
knockdown may exert a significant influence on MCF-7/
ADR cell viability and proliferation.
Arresting cell cycle progression can inhibit the prolif-
eration of cells [36]. To investigate the potential molec-
ular mechanisms of SALL4 on the cell proliferation, we 
examined the cell-cycle analyses in MCF-7/ADR using 
flow cytometry, and the results showed that knockdown 
of SALL4 significantly changed cell cycle distributions in 
MCF-7/ADR cells by increasing the percentage of cells in 
the G1 phase accompanied with reducing the percentage 
of cells in the S and G2/M phase (P < 0.05, Fig. 2d), dem-
onstrating typical cell cycle arresting at the G1 phase. In 
terms of all of the detected indices, there were no differ-
ence between the Lv-shNC group and the CON group 
(P > 0.05). These findings are consistent with the previous 
reports that down-regulation of SALL4 suppresses the 
growth of cancer cells and induces G1 phase arrest [37, 
38]. We also evaluated the levels of cycle-related proteins 
cyclinD1 and cyclin-dependent kinase 4 (CDK4) by qRT-
PCR and western blot analysis. CyclinD1 is one of the 
main factors in cell cycle regulation [39, 40], which bind-
ing with cyclin-dependent kinase, then leading G1 phase 
cells into S phase and promoting cell proliferation. A sig-
nificant decrease of mRNAs and proteins (cyclinD1 and 
CDK4) was observed in MCF-7/ADR cells in the target 
gene knockdown group (Fig. 2e, f ), indicating that knock-
down SALL4 induced G1 phase arrest in these cells. 
These results suggest that SALL4 has an impact on the 
proliferative activity of the resistant breast cancer cells 
through cell cycle arrest.
Silencing SALL4 re‑sensitizes MCF‑7/ADR cells to ADMh 
in vitro
Silencing SALL4 in MCF-7/ADR cells evidently 
enhanced its sensitivity to ADMh. As shown in the 
Table 1, the IC50 values of ADMh at 24 and 48 h in the 
Lv-shSALL4 group decreased from (152.57  ±  2.33) 
and (29.66  ±  1.14)  umol/L to (42.09  ±  3.42) and 
(6.48 ±  0.42)  umol/L, respectively. And RI also became 
apparently lower than that in the CON group (P < 0.01). 
Besides this, a marked inhibition of colony forma-
tion ability was observed in the colony formation assay. 
The colony count and area were smaller in Lv-shSALL4 
group (P < 0.01, Fig. 3). And the ANOVA test indicated 
there was a synergistic effect of SALL4 knockdown and 
ADMh treatment on inhibition of colony formation abil-
ity (P < 0.05). The results mentioned above suggest that 
knockdown SALL4 can re-sensitize MCF-7/ADR cells to 
ADMh and reduce it growth.
The cytotoxic effect of anticancer drugs is associated 
with the dose which can be accumulated in the cells 
[41]. In order to investigate the potential mechanisms 
of SALL4 and drug resistance of MCF-7/ADR cells, we 
Fig. 1 Expression of the transcription factor SALL4 (sal‑like 4) in 
breast cell lines. a MRNA levels of SALL4 expressed in the indicated 
cell lines were evaluated by quantitative real‑time PCR (qRT‑PCR). 
Data are expressed as mean ± standard deviation (SD) of at least 
three independent experiments. **P < 0.01, when compared to 
MCF‑7/ADR cells; and b protein levels of SALL4 were evaluated by 
western blot in the indicated cell lines
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detected intracellular accumulation rate of ADMh in 
MCF-7/ADR and parental MCF-7 cells. As shown in 
Fig.  4a, c, a markedly higher intracellular accumulation 
of ADMh was observed in the cells of Lv-shSALL4 group 
compared with the CON group (P < 0.01). Moreover, we 
also found that the intracellular accumulation of ADMh 
in the Verapamil pretreated cells was higher in MCF-7/
ADR cells. But the ADMh accumulation rate was similar 
Fig. 2 Down‑regulation of SALL4 inhibits proliferation and changes cell cycle distributions in MCF‑7/ADR cells. a MRNA levels of SALL4 in the indi‑
cated cells were assessed by qRT‑PCR (***P < 0.001); and b growth curves of MCF‑7/ADR cells and c the relative proliferation rate of the cells with or 
without SALL4 knockdown (*P < 0.05 and ***P < 0.001); and d cell cycle distribution in percentages of different groups (*P < 0.05 and **P < 0.01); 
and e effects of SALL4 on the mRNA levels of cyclinD1 and CDK4 genes. GAPDH was used as the referral gene. (**P < 0.01); and f the levels of indi‑
cated proteins, GAPDH was used as the loading control, and the experiments were performed in triplicate
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in parental MCF-7 cells with Verapamil pretreated or 
not (P  >  0.05, Fig.  4b, d). Furthermore, the ANOVA 
test indicated that knockdown of SALL4 had synergy 
with Verapamil to increase ADMh accumulation rate 
in MCF-7/ADR cells (P < 0.05).We also investigated the 
effect of SALL4 on membrane transporters, BCRP and 
P-gp, as well as c-myc by qRT-PCR and western blot. 
With SALL4 knockdown, the expression of both c-myc 
and ABCG2/BCRP in MCF-7/ADR cells decreased sig-
nificantly (P  <  0.01). But with SALL4 knockdown, the 
expression of MDR1/P-gp only had a slight declining 
tendency, when compared to the CON group (P > 0.05, 
Fig.  4e, f ). In other words, the function of ABCG2 and 
c-myc in SALL4-knocked-down MCF-7/ADR cells 
was effectively inhibited, while the function of MDR1in 
SALL4-knocked-down MCF-7/ADR cells was not signifi-
cantly inhibited. Verapamil is a competitive inhibitor of 
both P-gp and BCRP, and they are ABC trans-membrane 
efflux proteins sharing the ability to actively extrude 
drugs and toxins out of the cells, which may conduce to 
increasing the drug resistance in cancer cells. ADMh is 
the substrate of both P-gp and BCRP. The intracellular 
accumulation rate of ADMh will increase when anyone 
of the trans-membrane proteins is inhibited. In view of 
this, we assumed that the accumulation rate of SALL4-
knocked-down MCF-7/ADR cells was higher than the 
Table 1 The analysis of the IC50 and RI of MCF-7 and MCF-7/ADR cells towards ADMh




IC50 (uM) Resistance index (RI)
MCF‑7 MCF‑7/ADR MCF‑7/ADR
CON Lv‑shNC Lv‑shSALL4 CON Lv‑shNC Lv‑shSALL4
24 1.06 ± 0.09 152.57 ± 2.33 149.03 ± 3.28 42.09 ± 3.42** 143.93 ± 2.20 140.60 ± 3.60 39.70 ± 33.23**
48 0.22 ± 0.01 29.66 ± 1.14 30.01 ± 1.88 6.48 ± 0.42** 134.82 ± 5.17 136.41 ± 5.40 29.63 ± 1.59**
Fig. 3 Synergistic cytotoxic effect of SALL4 knockdown and ADMh on MCF‑7/ADR cells. a The photo‑micrographic differences, and b, c influence 
of colonies (mean ± SD, n = 3) on colony formation are shown. All data were from three independent experiments. MCF‑7/ADR cells were treated 
with various concentration of ADMh (0, 5 and 10 μmol/L) for 12 h and were allowed to form colonies in fresh medium for 14 days, **P < 0.01, 
***P < 0.001, when compared to the CON group
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Fig. 4 ADMh accumulation rates of MCF‑7/ADR and MCF‑7 cells and effects of SALL4 on ABCG2, MDR1 and c‑myc. a, b The intracellular accumu‑
lation of ADMh in the tested cells was analyzed by flow cytometry, and c, d the intracellular accumulation of ADMh in percentages of different 
groups. All data were from three independent experiments. **P < 0.01, when compared to the CON group; and e effects of SALL4 on the mRNA 
levels of indicated genes. GAPDH was used as the referral gene. All data were from 3 independent experiments. **P < 0.01, when compared with 
the CON group; and f effects of SALL4 on the levels of indicated proteins. Results were representative of 3 independent experiments. GAPDH was 
used as the loading control
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cells without SALL4 knockdown due to ABCG2/BCRP 
down-regulation. And the accumulation rate of SALL4-
knocked-down MCF-7/ADR cells was increased again by 
Verapamil treatment caused by MDR1/P-gp inhibition. 
This was consistent with Yhee et  al. [42], who reported 
drug accumulation rate increased in MCF-7/ADR cells by 
P-gp inhibition. However, the results of MCF-7 cells were 
not in agreement with Rogalska et al. [43], who reported 
that doxorubicin accumulation rate in MCF-7 cells pre-
incubated with Verapamil increased higher. The reason 
for this difference probably was that the concentration, 
5-umol/L of ADMh, was a supersaturated concentration 
for MCF-7 and the membrane transport proteins can-
not continue extruding ADMh out of cells in our experi-
ment. According to these data, we speculated SALL4 
conferred breast cancer cells on drug resistance, at least 
partly through manipulating ABCG2 and c-myc genes. 
Knockdown SALL4 of MCF-7/ADR cells can enhance 
intracellular ADMh accumulation, leading to a higher 
therapeutic effect of ADMh.
SALL4 down‑regulation re‑sensitizes drug‑resistant tumor 
to chemotherapy in vivo
To investigate the effects of SALL4 down-regulation on 
tumor growth and drug resistance in  vivo, stroke-phys-
iological saline solution (NS) or ADMh (3  mg/kg) were 
intraperitoneally injected into nude mice carrying sub-
cutaneous MCF-7/ADR tumor every 3  days for up to 
20  days. The tumors removed from these animals were 
shown in Fig. 5a, and their mean weights were provided 
in Fig.  5b. The results showed an obvious inhibition of 
tumor growth in mice with SALL4 knockdown compared 
with the Lv-shNC group (P  <  0.001). And the ANOVA 
test indicated SALL4 knockdown had potent syn-
ergy with ADMh to suppress the tumor growth in  vivo 
(P  <  0.05). Those were consistent well with the results 
of colony formation assay in  vitro that knockdown of 
SALL4 can reduce the chemo-resistance and prolifera-
tion of MCF-7/ADR cells.
In order to increase the efficacy of breast cancer 
therapy, it is of great importance to identify candidate 
genes that are essential in cancer cell proliferation and 
drug resistance. SALL4, a stem cell factor plays vital 
roles in development and tumorigenesis. Its expression 
has been previously linked with tumor treatment status 
and drug resistance. SALL4 knockdown affects tumor 
growth in various malignancies including breast can-
cer. However, whether up-regulation of SALL4 is related 
with chemo-resistance of breast cancer and the under-
ling mechanisms remained unclear. In this study, using 
multidrug resistant breast cancer cells MCF-7/ADR and 
its parental MCF-7 cells, we demonstrated that SALL4 
was overexpressed in MCF-7/ADR cells. Knockdown of 
SALL4 in MCF-7/ADR decreased its proliferation and 
induced G1 phase arrest accompanied by down-regula-
tion of cell cycle related proteins (cyclinD1 and CDK4). 
Analyses of the IC50 values and resistance indices indi-
cated knockdown of SALL4 enhanced the chemo-sen-
sitivity of MCF-7/ADR cells to ADMh. The observed 
difference in cytotoxicity and intracellular accumulation 
of ADMh might be related to the inhibition of SALL4 
affecting the function of BCRP, c-myc and P-gp. The 
strongest suppression of tumor growth in vivo observed 
in SALL4 knockdown combined with ADMh group sug-
gested knockdown of SALL4 and ADMh had synergistic 
inhibition of tumor growth. In summary, our study pro-
vided solid evidence that knockdown of SALL4 can sig-
nificantly inhibit the proliferative captivity and reverse 
the drug resistance of breast cancer in vitro and in vivo; 
and these results suggest that SALL4 interference may 
have a profound effect on the chemotherapy of breast 
cancer.
Conclusions
In conclusion, this study suggests that knockdown 
of SALL4 inhibits the proliferation of MCF-7/ADR 
cells through arresting the cell cycle in the G1 phase 
Fig. 5 Knockdown of SALL4 re‑sensitizes the in vivo tumor to 
chemotherapy. a Tumors were excised from the animals and photos 
of them were presented to show the sizes of the resulting tumors; 
and b tumors were weighed. ***P < 0.001, when compared to the 
Lv‑shNC group
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and that down-regulation of SALL4 reverses the drug 
resistance of breast cancer by reducing the expres-
sion of ABCG2 and c-myc. However, further mech-
anisms of SALL4 affecting tumor growth and drug 
sensitivity of tumor to chemotherapy are required to 
investigate.
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